SCHEMBL15280867

SCHEMBL15280867

CO[C@H]1C(OC(C)(C)C)[C@@H](CC(C)(C)C)O[C@H]1n1cnc2c(N)ncnc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.51
ADORA1 P30542 4/20 0.49
EHMT1 Q9H9B1 1/20 0.49
DPP4 P27487 1/20 0.49
MEN1 O00255 1/20 0.49
SLC28A1 O00337 1/20 0.49
MAP3K7 O43318 1/20 0.49
SLC28A2 O43868 1/20 0.49
GAPDH P04406 1/20 0.49
MAPK1 P28482 1/20 0.49
ADORA2A P29274 1/20 0.49
ADORA2B P29275 1/20 0.49
STAT6 P42226 1/20 0.49
PI4KA P42356 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PI4K2B Q8TCG2 1/20 0.49
DOT1L Q8TEK3 1/20 0.49
SLC29A1 Q99808 1/20 0.49
PI4K2A Q9BTU6 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19887015 1.00 ADORA3 (0.51) ADORA3ADORA1EHMT1DPP4MEN1
SCHEMBL19522864 1.00 ADORA3 (0.51) ADORA3ADORA1EHMT1DPP4MEN1
SCHEMBL15280831 0.90 ADORA1 (0.48) ADORA3ADORA1EHMT1DPP4MEN1
SCHEMBL19887050 0.90 ADORA1 (0.48) ADORA3ADORA1EHMT1DPP4MEN1
SCHEMBL25819528 0.89 ADORA1 (0.54) ADORA3ADORA1DPP4MEN1SLC28A1
SCHEMBL25818697 0.89 ADORA1 (0.54) ADORA3ADORA1DPP4MEN1SLC28A1
SCHEMBL24699819 0.88 ADORA3 (0.49) ADORA3ADORA1DPP4MEN1SLC28A1
SCHEMBL19887063 0.88 ADORA1 (0.60) ADORA3ADORA1EHMT1DPP4MEN1
SCHEMBL15280892 0.88 ADORA1 (0.60) ADORA3ADORA1EHMT1DPP4MEN1
SCHEMBL19522845 0.88 ADORA1 (0.60) ADORA3ADORA1EHMT1DPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018516-A1 Agent for Regulating Expression and/or Function of RPS25 Gene Sumitomo Pharma Co., Ltd. (JP) 2024-01-18 US disclosed
US-9803199-B2 Cationic lipid DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-10-31 US disclosed
US-20160257951-A1 NOVEL LIPID DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-09-08 US disclosed
US-8987226-B2 Modified single-stranded polynucleotides DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-03-24 US disclosed
US-20130253038-A1 Modified Single-Stranded Polynucleotide DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257951-A1 NOVEL LIPID NPC1L1, CETP, LIPC ADORA3 1725/4885ADORA1 1034/4885EHMT1 3655/4885
US-20240018516-A1 Agent for Regulating Expression and/or Function of RPS25 Gene RPS25, RPS26, RPS24 ADORA3 4135/4885ADORA1 4048/4885EHMT1 4334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.